Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs

ObjectiveThis study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.MethodsWe retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedot...

Full description

Saved in:
Bibliographic Details
Main Authors: Daiki Ikarashi, Tatsuya Kawamura, Keita Ogasawara, Yumeka Arakawa, Arisa Machida, Ayato Ito, Ei Shiomi, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Jun Sugimura, Wataru Obara
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1493922/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832582939642167296
author Daiki Ikarashi
Tatsuya Kawamura
Keita Ogasawara
Yumeka Arakawa
Arisa Machida
Ayato Ito
Ei Shiomi
Shigekatsu Maekawa
Renpei Kato
Mitsugu Kanehira
Jun Sugimura
Wataru Obara
author_facet Daiki Ikarashi
Tatsuya Kawamura
Keita Ogasawara
Yumeka Arakawa
Arisa Machida
Ayato Ito
Ei Shiomi
Shigekatsu Maekawa
Renpei Kato
Mitsugu Kanehira
Jun Sugimura
Wataru Obara
author_sort Daiki Ikarashi
collection DOAJ
description ObjectiveThis study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.MethodsWe retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedotin for advanced urothelial carcinoma. We also evaluated the periods of tumor shrinkage maintenance (the period when best response was maintained) and regrowth (the period from best response to tumor growth confirmation) between primary and metastatic organs.ResultsMeasurable metastatic organs included the lung in 17, lymph node in 22, liver in 6, and bone in 5 cases. Primary lesion was detected in 20 cases. The mean tumor shrinkage rates for lung, lymph node, liver, and bone metastases and primary sites were 21% (−212 to 100), 13% (−130 to 86), −8.5% (−158 to 85), −64% (−250 to 21), and 22% (−38 to 79), respectively. The tumor shrinkage was maintained for 5.9 (0.7–14) months in lung metastases, 8.3 (2.6–14.5) months in lymph node metastases, 3.6 months in liver metastases, 0.7 months in bone metastases, and 1.8 (0.7–5.4) months in primary sites, and the period of regrowth was 7.3 (2.2–19.4), 4.8 (2.0–8.9), 2.8, 6.5, and 2.5 (1.1–5.9) months, respectively.ConclusionsEnfortumab vedotin showed significant tumor shrinkage in the primary tumor, lung metastases, and lymph node metastases, whereas the durability of tumor shrinkage was limited in the primary tumor.
format Article
id doaj-art-40adda83b5364e168d78d139ad47baa8
institution Kabale University
issn 2234-943X
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-40adda83b5364e168d78d139ad47baa82025-01-29T05:21:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14939221493922Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organsDaiki IkarashiTatsuya KawamuraKeita OgasawaraYumeka ArakawaArisa MachidaAyato ItoEi ShiomiShigekatsu MaekawaRenpei KatoMitsugu KanehiraJun SugimuraWataru ObaraObjectiveThis study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.MethodsWe retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedotin for advanced urothelial carcinoma. We also evaluated the periods of tumor shrinkage maintenance (the period when best response was maintained) and regrowth (the period from best response to tumor growth confirmation) between primary and metastatic organs.ResultsMeasurable metastatic organs included the lung in 17, lymph node in 22, liver in 6, and bone in 5 cases. Primary lesion was detected in 20 cases. The mean tumor shrinkage rates for lung, lymph node, liver, and bone metastases and primary sites were 21% (−212 to 100), 13% (−130 to 86), −8.5% (−158 to 85), −64% (−250 to 21), and 22% (−38 to 79), respectively. The tumor shrinkage was maintained for 5.9 (0.7–14) months in lung metastases, 8.3 (2.6–14.5) months in lymph node metastases, 3.6 months in liver metastases, 0.7 months in bone metastases, and 1.8 (0.7–5.4) months in primary sites, and the period of regrowth was 7.3 (2.2–19.4), 4.8 (2.0–8.9), 2.8, 6.5, and 2.5 (1.1–5.9) months, respectively.ConclusionsEnfortumab vedotin showed significant tumor shrinkage in the primary tumor, lung metastases, and lymph node metastases, whereas the durability of tumor shrinkage was limited in the primary tumor.https://www.frontiersin.org/articles/10.3389/fonc.2024.1493922/fulldurabilityenfortumab vedotinprimarymetastatic organtumor shrinkage
spellingShingle Daiki Ikarashi
Tatsuya Kawamura
Keita Ogasawara
Yumeka Arakawa
Arisa Machida
Ayato Ito
Ei Shiomi
Shigekatsu Maekawa
Renpei Kato
Mitsugu Kanehira
Jun Sugimura
Wataru Obara
Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
Frontiers in Oncology
durability
enfortumab vedotin
primary
metastatic organ
tumor shrinkage
title Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
title_full Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
title_fullStr Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
title_full_unstemmed Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
title_short Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
title_sort tumor shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
topic durability
enfortumab vedotin
primary
metastatic organ
tumor shrinkage
url https://www.frontiersin.org/articles/10.3389/fonc.2024.1493922/full
work_keys_str_mv AT daikiikarashi tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT tatsuyakawamura tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT keitaogasawara tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT yumekaarakawa tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT arisamachida tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT ayatoito tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT eishiomi tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT shigekatsumaekawa tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT renpeikato tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT mitsugukanehira tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT junsugimura tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans
AT wataruobara tumorshrinkingeffectsofenfortumabvedotinbetweenprimaryurothelialcarcinomaandmetastaticorgans